SILVER SPRING
Fasenra cleared for Hypereosinophilic Syndrome
- Sponsor
- AstraZeneca $AZN
- Drug
- Fasenra · benralizumab
- Indication
- Hypereosinophilic Syndrome
FDA approved AstraZeneca's Fasenra for adult and pediatric patients aged 12+ with hypereosinophilic syndrome without an identifiable non-hematologic cause.
What this means
Fasenra is an antibody treatment that targets a protein receptor involved in eosinophil production, reducing high levels of these immune cells that can cause tissue damage. Today FDA approved Fasenra for hypereosinophilic syndrome, a rare condition where excess eosinophils lead to inflammation and organ problems. This decision expands treatment options for patients aged 12 and older who have this condition without a known underlying cause.